Skip to main content
. 2017 Jul 22;8(54):91860–91875. doi: 10.18632/oncotarget.19463

Table 1A. Meta-analysis results for associations between the TLRs and overall survival for NSCLC patients.*.

Univariate Multivariate
Gene Affy Probe ID n P value HR^ P value (gene)** HR (gene) P value (histology) P value (gender)
TLR1 210176_at 1926 6.50E-05 0.72 (0.61-0.85) 0.003 0.74 (0.63 0.87) 1.00E-15 0.0004
TLR2 204924_at 1926 5.40E-09 0.61 (0.52-0.72) 6.00E-04 0.74 (0.62-0.88) 1.00E-15 0.0006
TLR3 206271_at 1926 4.20E-07 0.66 (0.56-0.77) 0.0052 0.78(0.66-0.93) 1.00E-15 0.0003
TLR4 232068_s_at 1587 ns 0.85 (0.71-1.03) ns - - -
TLR5 210166_at 1926 1.80E-05 0.7 (0.59-0.82) 0.0173 0.81 (0.68 0.96) 1.00E-15 0.0005
TLR6 239021_at 1926 5.50E-06 0.64 (0.53-0.78) 0.001 0.72 (0.59 0.87) 1.00E-15 0.0017
TLR7 220146_at 1926 6.60E-10 0.6 (0.51-0.71) 1.00E-15 0.6 (0.51-0.71) 1.00E-15 0.0006
TLR8 229560_at 1587 0.00022 0.7 (0.58-0.85) 0.0095 0.78 (0.64-0.94) 1.00E-15 0.0024
TLR9 223903_at 1587 ns 0.94 (0.78-1.13) ns - - -
TLR10 223751_x_at 1926 ns 0.85 (0.71-1.03) ns - - -

* For all significant TLRs, FDR 5% was tested, NSCLC combined samples P <0.0173; ADC samples P <0.0066; ** Multivariate for all NSCLC for gender and histology; ^ Hazard ratio. Ns, not significant. Dash indicates test was not performed due to non-significance in univariate analysis.